![](/fileadmin/_processed_/csm_NCI-radiopharma_21ffe1bccf.png)
ITM gets equity to launch Phase III lead radiopharmaceutical ITM-11
Radiopharma conjugate specialist Isotope Technologies Munich SE has raised €188m in an equity financing led by globally active investor Temasek....
![](/fileadmin/_processed_/csm_Apeiron_Board_148036936f.png)
Ligand Pharma to acquire Apeiron Biologics
As part of the US100m acquisition, Ligand Pharmaceuticals Inc has committed to invest up to US$4m in invIOs Holding AG, Apeiron Biologics...
![](/fileadmin/_processed_/csm_LG_Draft_aece1073b5.jpg)
Locate Bio Ltd raises £9.2m venture capital
Locate Bio said it will use the fresh money to finance a clinical study of LDGraft, a bone graft substitute containing a sustained-release...
![](/fileadmin/_processed_/csm_EBC_c_CDC_7b5c041c11.png)
Hornet Therapeutics reports first data of EBV-triggered disease blocker
Hornet Therapeutics Ltd that was spun out in 2020 from the group of Christoph Hess (now University Cambridge) at University Basel, has...
![](/fileadmin/_processed_/csm_dollars-499481_1280-_Gerd_Altmann_pixabay_55a91b9ae7.jpg)
Forbion closes first Bioeconomy Fund with US$75m
Life Science investor Forbion opens a new sector for its lead partners who were eager to put money into industries within the ESG standards. At...
![](/fileadmin/Content/NewsAndStories/2024/Bildschirmfoto_2024-07-09_um_09.31.12.png)
EMA-Gate: PharmaMar wins suit against EMA
The European Commission has corrected its decision C(2018) 4831 from 2018 not to grant marketing authorisation for Aplidin (plitidepsin), a peptidic...
![](/fileadmin/_processed_/csm_Microglia_and_neurons_c__Gary_Shaw_ed89bb0973.jpg)
Researchers identify blockers of CNS effects of PD1 cancer therapy
In mouse models, a group headed by Marco Prinz from University Freiburg demonstrated that adverse side effects of immune cancer therapies with PD1...